Login to Your Account



Deals And M&A NEWS
LATE-STAGE PSEUDOMONAS BLOCKER

Kalobios Pharmaceuticals Inc. asked for and got back the rights to KB001-A from Sanofi Pasteur, under terms that at least one analyst deemed "attractive" – especially given that the pharma partner was hardly moving the antibody along at a brisk pace.

Zealand Pharma A/S could earn up to €295 million (US$396 million) in milestone payments arising from a second drug development deal in diabetes with Boehringer Ingelheim GmbH. It will bank €5.6 million during 2014.
BOGOTA, Colombia – French health care company Stallergenes SA announced the acquisition of Argentina's Alergo Pharma Srl as part of a plan to boost its presence in Latin America, while focusing on the diagnosis and treatment of allergies through diverse allergen immunotherapy-based solutions.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: